Oncology

Code Test Genes TAT
8702 Microsatellite instability (MSI) analysis 3-4 weeks
9510 CustomNext: Cancer AIP, ALK, APC, ATM, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, DICER1, EPCAM, FANCC, FH, FLCN, GALNT12, GREM1, HOXB13, MAX, MEN1, MET, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, XRCC2 14-21 days
9014 ATM seq and del/dup ATM 14-21 days
9811 TumorNext- HRD ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MRE11A, NBN, PALB2, RAD51C, RAD51D 3-4 weeks
9044 BAP1 seq and del/dup BAP1 14-21 days
8980 TumorNext- Lynch BRAF, EPCAM, KRAS, MLH1, MSH2, MSH6, NRAS, PMS2 3-4 weeks
9016 CHEK2 seq and del/dup CHEK2 14-21 days
9046 MITF specific site analysis MITF 7-14 days
9004 MRE11A seq and del/dup MRE11A 14-21 days
9024 NF2 seq and del/dup NF2 14-21 days
8847 BrainTumorNext AIP, ALK, APC, CDKN1B, CDKN2A, DICER1, MEN1, MLH1, MSH2, MSH6, NBN, NF1, NF2, PHOX2B, PMS2, POT1, PRKAR1A, PTCH1, PTEN, SMARCA4, SMARCB1, SMARCE1, SUFU, TP53, TSC1, TSC2, VHL 14-21 days
8874 CancerNext-Expanded AIP, ALK, APC, ATM, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2, DICER1, EPCAM, FANCC, FH, FLCN, GALNT12, GREM1, HOXB13, MAX, MEN1, MET, MITF, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, NF2, PALB2, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, XRCC2 14-21 days
8836 BRCAPlus ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, TP53 7-10 days
8845 ProstateNext ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51D, TP53 14-21 days
8830 OvaNext ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53 14-21 days
8849 MelanomaNext BAP1, BRCA2, CDK4, CDKN2A, MITF, PTEN, RB1, TP53 14-21 days
8835 GYNplus BRCA1, BRCA2, BRIP1, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53 14-21 days
8838 BRCA1/2 seq and del/dup BRCA1, BRCA2 6-10 days
8042 PancNext APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53 14-21 days
8822 ColoNext APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53 14-21 days
8824 CancerNext APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, EPCAM, GREM1, HOXB13, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMAD4, SMARCA4, STK11, TP53 14-21 days
8820 BreastNext ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, TP53 14-21 days
8604 BMPR1A & SMAD4 seq and del/dup BMPR1A, SMAD4 14-21 days
8510 MSH2 seq & del/dup & EPCAM del/dup EPCAM, MSH2 14-21 days
8517 HNPCC concurrent EPCAM, MLH1, MSH2, MSH6, PMS2 14-21 days
8519 HNPCC/Lynch del/dup EPCAM, MLH1, MSH2 7-14 days
8508 MLH1 seq and del/dup MLH1 14-21 days
8512 MSH6 seq and del/dup MSH6 14-21 days
7180 SMARCB1 seq and del/dup SMARCB1 14-21 days
5900 RenalNext BAP1, EPCAM, FH, FLCN, MET, MITF, MLH1, MSH2, MSH6, PMS2, PTEN, SDHA, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL 14-21 days
6301 FH seq and del/dup FH 14-21 days
5504 PGLNext FH, MAX, MEN1, NF1, RET, SDHA, SDHAF2, SDHB, SDHC, SDHD, TMEM127, VHL 14-21 days
5921 FLCN seq and del/dup FLCN 14-21 days
5704 NF1 seq and del/dup NF1 14-21 days
5684 PTCH1 seq and del/dup PTCH1 14-21 days
5904 TSC1/2 seq and del/dup TSC1, TSC2 14-21 days
3040 APC seq and del/dup
Familial adenomatous polyposis (FAP)
Adenomatous polyposis
APC 14-21 days
4726 CDH1 seq and del/dup CDH1 14-21 days
4708 CDKN2A & CDK4 seq and del/dup CDK4, CDKN2A 14-21 days
5260 DICER1 seq and del/dup DICER1 14-21 days
4661 MUTYH seq and del/dup
MUTYH-associated polyposis (MAP)
Adenomatous polyposis
MUTYH 14-21 days
4646 PMS2 seq and del/dup PMS2 14-21 days
5426 RB1 seq and del/dup RB1 14-21 days
2646 MEN1 seq and del/dup MEN1 14-21 days
2366 PALB2 seq and del/dup PALB2 14-21 days
2106 PTEN seq and del/dup PTEN 14-21 days
2680 RET seq
RET-related Hirschsprung disease
Multiple endocrine neoplasia type 2 (MEN2) and familial medullary thyroid cancer (FMTC)
RET 14-21 days
2766 STK11 seq and del/dup STK11 14-21 days
2866 TP53 seq and del/dup TP53 14-21 days
2606 VHL seq and del/dup VHL 14-21 days

Please select a category to find your test or learn more about our highlighted tests below

why choose ambry

Ambry places significant value on implementing new lab processes designed to increase quality, and advancing technology across the field with innovative approaches. Our ongoing participation in numerous research studies and collaborations is so that we can better assess clinical validity of gene-disease relationships. This is to ensure that the results healthcare providers receive are as accurate and informative as possible. That’s why we led the largest study of its kind (20,000 cases) guiding us on additional confirmatory testing when we saw specific well-defined thresholds, reducing the chance of delivering a false positive patient report or one that misses real mutations (Mu et al., November 2016). The more accurate the reports, the more insight healthcare providers will have to treat their patients.

Choose from one of our more frequently ordered tests listed below.

CancerNext®

When finding the answer is critical for guiding your patient’s healthcare, CancerNext is a comprehensive 34-gene panel that identifies inherited risks for at least 8 types of cancers, giving you more information to make better treatment and management decisions.

CustomNext-Cancer ®

For patients with a complex personal or family history of cancer, CustomNext gives you the flexibility to choose which genes to analyze so you can accurately diagnose, treat, and manage your patient’s cancer risks.

BreastNext®

Understanding high-risk breast cancer patients such as those with early-onset or multiple diagnoses of breast cancer, male breast cancer, and/or with a family history of disease is made clearer with BreastNext, a 17-gene panel, offering more precision to identify and manage hereditary breast cancer.

OvaNext®

Every patient diagnosed with epithelial ovarian cancer meets criteria for hereditary cancer genetic testing. OvaNext, a 25-gene panel, offers the most comprehensive testing for gynecologic cancers to increase the chance of identifying and managing hereditary cancer risks.

ProstateNext®

Since hereditary prostate cancer is not well understood or often recognized, clinicians need clear results to guide treatment decisions. ProstateNext is a 14-gene panel which offers more precision to identify and manage hereditary prostate cancer.

ColoNext®

Patients with a suspicious personal or family history of colorectal cancer or polyps benefit from early detection and cancer prevention. Identify patients with an increased risk by using ColoNext, a 17-gene panel designed to provide more precise data to help guide personalized medical management recommendations such as earlier or more frequent colonoscopies.

BRCAplus ®

To understand your patient’s risk and minimize uncertain results, you need a genetic test designed specifically for patients with a high risk personal and/or family breast cancer history. BRCAplus tests critical breast cancer genes with published guidelines for medical management, so you can help your patient make confident, personalized screening and prevention decisions.

TumorNext-HRD

TumorNext-HRD clearly determines patients who may benefit from treatment with PARP inhibitors in one simple test. It simultaneously understands hereditary risk as it detects and differentiates between germline and somatic mutations in homologous recombination repair genes including BRCA1 and BRCA2.

TumorNext-Lynch

When you need to rule out or confirm Lynch syndrome or to determine if your patient can start PD-LI or PD-1 immunotherapy, you need a test that gives you the most comprehensive and accurate information. TumorNext-Lynch is a single test that looks at both tumor and germline mutations, giving you clearer information to better guide treatment decisions.

Search Results

Start your search...